ClinicalTrials.gg
RecruitingNCT05896488Sweat-CFUpdated Jun 9, 2023

Sweat Response, Sweat Composition and Thermoregulatory Response to Exercise in Heat in Adults With Cystic Fibrosis on Modulator Therapy.

An observational study in Cystic Fibrosis, sponsored by University of Portsmouth. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by University of Portsmouth · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
18
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Cystic Fibrosis with a site in United Kingdom — 21 open to participants now, 32 under way, 4 of them phase 3. Cystic Fibrosis · United Kingdom.

Planned enrollment
43rd of 49
18 · median 79
Started
2023
with 11 others
Observational
49 of 236
14 open now
Primary completion
2024-03
later than 3 of 31 live
Registered
204th of 236
by date

Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, this one is the 43rd largest by planned enrollment of the 49 observational ones that give a count, is one of 12 that started in 2023, is one of 49 observational ones, reaches primary completion later than 3 of the 31 other live ones, and was the 204th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

21 of the 236 studies in Cystic Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Cystic Fibrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Cystic fibrosis (CF) is a common inherited condition in the Caucasian population resulting in poor function and/or production of the CF transmembrane conductance regulator (CFTR) protein. The CFTR protein plays a crucial role in the secretion and re-absorption of sodium chloride within the sweat gland. The sweat gland has played a key role in diagnosing and understanding CF with sweat chloride elevation being a key criterion to diagnosing CF. People with CF are thought to be at risk of exertional heat illness during exposure to hot environments or during prolonged periods of exercise and are currently encouraged to take salt supplements during periods of excessive sweating.

Kaftrio®, a newly approved pharmacological therapy has shown a rapid and sustained reduction in sweat chloride levels on initiation of this treatment. This study will aim to play a crucial part in understanding the sweat response, sweat composition and the thermoregulatory response to exercise in the heat in people with CF on Kaftrio®.

Read the detailed description

Cystic fibrosis (CF) is a common inherited condition in the Caucasian population, affecting approximately 52, 246 people in Europe. Mutations in the CF transmembrane conductance regulator (CFTR) gene results in poor function or production of the CFTR protein which functions as an anion channel to transport ions across the cell membrane.

The sweat gland has played a substantial part in diagnosing and understanding CF with sweat chloride elevation being a key criterion to diagnosing CF. Traditionally, abnormal function of the CFTR protein in the sweat gland results in failure to reabsorb sodium chloride leading to excessive salt loss. People with CF are thought to be at risk of exertional heat illness during exposure to hot environments or during prolonged periods of exercise and are currently encouraged to take salt supplements during periods of excessive sweating.

Over the last decade pharmacological therapies (CFTR modulator therapies (CFTRm)) which target the underlying cellular defect characterising CFTR in people with CF have been developed. Kaftrio® is now the most widely used modulator therapy. Studies have shown a rapid and sustained reduction in sweat chloride levels on initiation of these highly effective CFTRm. The need for salt supplementation may be influenced when taking CFTRm. Therefore, there is a need to further understand the sweat response relative to the needs in people with CF.

This study will recruit 9 people with CF who currently taking Kaftrio® and 9 healthy age-, sex- and weight-matched controls who are ≥ 18 years old. We will ask all participants to attend the laboratories for 2 visits. Visit 1 is designed to calculate metabolic heat production during different cycling intensities in order to set the workload for visit 2 relative to their metabolic heat production. Visit 2 is designed to collect sweat and thermoregulatory indices during 1 hour of cycling in the heat.

This study will compare the sweating and thermoregulatory response to exercising in the heat in a group of people with CF who are stable on Kaftrio® compared to a healthy matched control group.

The aims of this study are to:

  1. Determine the sweat sodium concentration in adults with CF on Kaftrio® from exercise at a fixed-rate of metabolic heat production under heat stress conditions and whether this is different to healthy age- weight- and sex- matched controls;
  2. Determine the local and whole-body sweat rate in adults with CF on Kaftrio® during exercise under heat stress conditions and whether this is different to healthy age- weight- and sex- matched controls;
  3. Determine how adults with CF on Kaftrio® respond in terms of skin blood flow during exercise under heat stress conditions and whether this is different to healthy age- weight- and sex- matched controls;
  4. Determine thermal strain from skin and core body temperature in adults with CF on Kaftrio® during exercise under heat stress conditions and whether this is different to healthy age- weight- and sex- matched controls.
03

Conditions studied

  • Cystic Fibrosis

Keywords

  • Exercise, CFTR modulator therapy, thermoregulation, heat-related illness, sweat sodium
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Participants will be recruited from adult CF outpatient clinics within the CF network. If a potential participant outside of the CF network wishes to participant they will be screened by the CF consultants within the CF network.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is taking CFTRm
  • Males and females ≥ 18 years of age
  • CF diagnosis based on clinical features, supported by a history of an abnormal sweat test (sweat [Cl-] > 60 mmol·L-1 > 100 mg sweat), where possible, diagnostic genotyping would also be desired
  • Can clearly state that they are not pregnant
  • No to performing exhaustive exercise
  • Can understand and cooperate with the study protocol
  • No exacerbation (increase in cough, sputum or breathlessness, or change in the colour of sputum) within the preceding 2 weeks
  • No weight loss in the preceding 2 weeks

Inclusion Criteria for healthy control participants:

  • Healthy males and females who are age- weight- and sex- matched to the enrolled individuals with CF
  • Can clearly state that they are not pregnant
  • No clinical diagnosis of a chronic disease
  • Can understand and cooperate with the study protocol
  • No contraindications to performing exhaustive exercise

Exclusion criteria

Exclusion Criteria for participants with CF:

  • Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders (arthritis, joint or muscle disease) and cardiovascular disease (congenital heart disease or cardiomyopathy).
  • Unstable co-morbid asthma (daily pulmonary function variability of >20%)
  • Is pregnant during the initial screening process
  • Unable to understand or cooperate with the study protocol due to learning difficulties or otherwise
  • Not of a suitable age for testing
  • Is a smoker or inhales any other substances

Exclusion Criteria for healthy control participants:

  • Any pulmonary, metabolic or cardiovascular conditions
  • Any other diagnosed disease
  • Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders (active arthritis, joint or muscle disease) and cardiovascular disease (congenital heart disease or cardiomyopathy)
  • Is pregnant during the initial screening process
  • Presents with co-morbidities to performing exhaustive exercise
  • Is a smoker or inhales any other substances
  • Unable to understand or cooperate with the study protocol due to learning difficulties or otherwise
  • Not an age- weight- or sex-match for the CF group
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
18 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cystic fibrosis

    No intervention - only assessments

  • Healthy Control

    No intervention- only assessments

06

What researchers measure

Primary outcomes

  1. Sweat sodium concentration (mmol∙L-1)

    Between group differences in sweat sodium concentration

    Time frame: Day 2 - baseline

Secondary outcomes

  1. Whole-body sweat rate (mL)

    Between group differences in whole-body sweat rate derived from pre - post nude body mass

    Time frame: Day 2 - baseline

  2. Forearm sweat rate (mg∙min-1∙cm2)

    Between group differences in forearm sweat rate

    Time frame: Day 2 - baseline

  3. Mid-back sweat rate (mg∙min-1∙cm2)

    Between group differences in mid-back sweat rate

    Time frame: Day 2 - baseline

  4. Sweat gland activity (gland∙cm2)

    Between group differences in sweat-gland activation derived from the modified-iodine patch technique

    Time frame: Day 2 - baseline

  5. Core temperature (°C)

    Between group differences in core temperature derived from rectal temperature

    Time frame: Day 2 - baseline

  6. Mean skin temperature (°C)

    Between group differences in skin temperature

    Time frame: Day 2 - baseline

  7. Heart rate (b∙min-1)

    Between group differences in heart rate

    Time frame: Day 2 - baseline

  8. Cutaneous blood flux

    Between group differences in cutaneous blood flux

    Time frame: Day 2 - baseline

  9. Urine osmolality (mOsmol/kg)

    Between group differences in urine osmolality

    Time frame: Day 2 - baseline

  10. Perception of temperature sensation

    Between group differences in perception of temperature sensation

    Time frame: Day 2 - baseline

  11. Perception of thermal comfort

    Between group differences in perception of thermal comfort

    Time frame: Day 2 - baseline

  12. Change in thermal comfort

    Between group differences in change in thermal comfort

    Time frame: Day 2 - baseline

  13. Rate of change in thermal comfort

    Between group differences in rate of change in thermal comfort

    Time frame: Day 2 - baseline

  14. Heat sensitivity

    Between group differences in heat sensitivity derived from sweat rate / change in thermal comfort

    Time frame: Day 2 - baseline

  15. Heat illness symptom index

    Between group differences in heat-related illness symptoms

    Time frame: Day 2 - baseline

  16. Maximal oxygen uptake (VO2 max)

    Between group differences in oxygen uptake derived from a maximal cardiopulmonary exercise test

    Time frame: Day 1 - baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Mar 2024, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 9, 2023
StartActual
Mar 18, 2023
Primary completionEst.
Mar 18, 2024
CompletionEst.
Mar 18, 2024
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05896488
Lead sponsor
University of Portsmouth
Responsible party
Dr Zoe Saynor (Reader (Associate Professor) in Clinical Exercise Physiology, University of Portsmouth) — Principal investigator
First posted
Jun 9, 2023
Start date
Mar 18, 2023
Primary completion
Mar 18, 2024 (estimated)
Completion
Mar 18, 2024 (estimated)
Last update
Jun 9, 2023

Study contacts

Zoe Saynor
Contact
zoe.saynor@port.ac.uk
02392843080
Lauren Clayton
Contact
lauren.clayton@port.ac.uk
02392843085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion